Managing Cancer and Living Meaningfully (CALM): A Randomized Controlled Trial of a Psychological Intervention for Patients With Advanced Cancer

被引:186
|
作者
Rodin, Gary [1 ,2 ]
Lo, Christopher [1 ,2 ]
Rydall, Anne [1 ]
Shnall, Joanna [1 ]
Malfitano, Carmine [1 ]
Chiu, Aubrey [1 ]
Panday, Tania [1 ]
Watt, Sarah [1 ]
An, Ekaterina [1 ]
Nissim, Rinat [1 ,2 ]
Li, Madeline [1 ,2 ]
Zimmermann, Camilla [1 ,2 ]
Hales, Sarah [1 ,2 ]
机构
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
BRIEF INDIVIDUAL PSYCHOTHERAPY; EARLY PALLIATIVE CARE; DIGNITY THERAPY; DEPRESSION; DISTRESS; SCALE; ANXIETY; LUNG; END; DEATH;
D O I
10.1200/JCO.2017.77.1097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeIndividuals with advanced cancer experience substantial distress in response to disease burden and impending mortality. Managing Cancer And Living Meaningfully (CALM) is a novel, brief, manualized psychotherapeutic intervention intended to treat and prevent depression and end-of-life distress in patients with advanced cancer. We conducted a randomized controlled trial to compare CALM with usual care (UC) in this population.MethodsPatients with advanced cancer were recruited from outpatient oncology clinics at a comprehensive cancer center into an unblinded randomized controlled trial. Permuted block randomization stratified by Patient Health Questionnaire-9 depression score allocated participants to CALM plus UC or to UC alone. Assessments of depressive symptoms (primary outcome), death-related distress, and other secondary outcomes were conducted at baseline, 3 months (primary end point), and 6 months (trial end point). Analyses were by intention to treat. Analysis of covariance was used to test for outcome differences between groups at follow-up, controlling for baseline. Mixed-model results are reported.ResultsParticipants (n = 305) were recruited between February 3, 2012, and March 4, 2016, and randomly assigned to CALM (n = 151) or UC (n = 154). CALM participants reported less-severe depressive symptoms than UC participants at 3 months ( = 1.09; P = .04; Cohen's d = 0.23; 95% CI, 0.04 to 2.13) and at 6 months ( = 1.29; P = .02; d = 0.29; 95% CI, 0.24 to 2.35). Significant findings for greater end-of-life preparation at 6 months also favored CALM versus UC. No adverse effects were identified.ConclusionFindings suggest that CALM is an effective intervention that provides a systematic approach to alleviating depressive symptoms in patients with advanced cancer and addresses the predictable challenges these patients face.
引用
收藏
页码:2422 / +
页数:17
相关论文
共 50 条
  • [11] Testing the Treatment Integrity of the Managing Cancer and Living Meaningfully Psychotherapeutic Intervention for Patients With Advanced Cancer
    Koranyi, Susan
    Philipp, Rebecca
    Quintero Garzon, Leonhard
    Scheffold, Katharina
    Schulz-Kindermann, Frank
    Haerter, Martin
    Rodin, Gary
    Mehnert-Theuerkauf, Anja
    FRONTIERS IN PSYCHOLOGY, 2020, 11
  • [12] Effectiveness of a brief manualized intervention, Managing Cancer and Living Meaningfully (CALM), adapted to the Italian cancer care setting: Study protocol for a single-blinded randomized controlled trial
    Caruso, Rosangela
    Nanni, Maria Giulia
    Rodin, Gary
    Hales, Sarah
    Malfitano, Carmine
    De Padova, Silvia
    Bertelli, Tatiana
    Murri, Martino Belvederi
    Bovero, Andrea
    Miniotti, Marco
    Leombruni, Paolo
    Zerbinati, Luigi
    Sabato, Silvana
    Grassi, Luigi
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2020, 20
  • [13] Feasibility of online managing cancer and living meaningfully (CALM) in Chinese patients with metastatic breast cancer: a pilot randomized control trial
    Zhang, Yening
    Pang, Ying
    He, Yi
    You, Miaoning
    Tang, Lili
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [14] Managing cancer and living meaningfully. Qualitative pilot results of a sense-based short-term therapy for advanced cancer patients (CALM)
    Scheffold, Katharina
    Engelmann, Dorit
    Schulz-Kindermann, Frank
    Rosenberger, Christina
    Krueger, Alexander
    Rodin, Gary
    Haeter, Martin
    Mehnert, Anja
    PSYCHOTHERAPEUT, 2017, 62 (03): : 243 - 248
  • [15] Managing Cancer and Living Meaningfully (CALM): A qualitative study of a brief individual psychotherapy for individuals with advanced cancer
    Nissim, Rinat
    Freeman, Emily
    Lo, Chris
    Zimmermann, Camilla
    Gagliese, Lucia
    Rydall, Anne
    Hales, Sarah
    Rodin, Gary
    PALLIATIVE MEDICINE, 2012, 26 (05) : 713 - 721
  • [16] Positive influence of managing cancer and living meaningfully (CALM) on fear of cancer recurrence in breast cancer survivors
    Wang, Menglian
    Gan, Chen
    Zhao, Jie
    Li, Wen
    Tang, Lingxue
    Xu, Jian
    Cheng, Huaidong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (07): : 3067 - 3079
  • [17] Brief, manualised and semistructured individual psychotherapy programme for patients with advanced cancer in Japan: study protocol for Managing Cancer and Living Meaningfully (CALM) phase 2 trial
    Miyamoto, Seraki
    Yamazaki, Tadahiro
    Shimizu, Ken
    Matsubara, Toshio
    Kage, Hidenori
    Watanabe, Kousuke
    Kobo, Hiroshi
    Matsuyama, Yutaka
    Rodin, Gary
    Yoshiuchi, Kazuhiro
    BMJ OPEN, 2022, 12 (03):
  • [18] Psycho-oncological interventions for patients in palliative care: managing cancer and living meaningfully (CALM)
    Mehnert-Theuerkauf, Anja
    ONKOLOGIE, 2024, 30 (09): : 845 - 849
  • [19] Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors
    Ding, Ke
    Zhang, Xiuqing
    Zhao, Jingjing
    Zuo, He
    Bi, Ziran
    Cheng, Huaidong
    INTEGRATIVE CANCER THERAPIES, 2020, 19
  • [20] Managing cancer and living meaningfully (CALM) in adults with malignant glioma: a proof-of-concept phase IIa trial
    Loughan, Ashlee R.
    Willis, Kelcie D.
    Braun, Sarah Ellen
    Rodin, Gary
    Lanoye, Autumn
    Davies, Alexandria E.
    Svikis, Dace
    Mazzeo, Suzanne
    Malkin, Mark
    Thacker, Leroy
    JOURNAL OF NEURO-ONCOLOGY, 2022, 157 (03) : 447 - 456